Jason Napodano

It turns out you can have too much of a good thing. The 1,000-plus immunotherapy trials and competition to develop proprietary versions of virtually the same drugs may prove inhibitory to cancer research, according to the New York Times. The conditions leave clinical researchers competing for the...

Neither Republicans nor Democrats are eager to cut the National Institutes of Health funding by the president’s suggested $5.8 billion, but with the proposal still on the table, the sum is not yet safe. And as 18 percent of the current $31.7 billion budget hangs in the balance, more Americans...

The beginning of the year has started with four consecutive sell-offs in the S&P 500. Sectors have been hit by a bevy topics ranging from interest rates, Chinese markets, and terrorism. There has been a different type of trend among biotech stocks. Over the past week of trading, many...

Shares of bluebird bio Inc (NASDAQ: BLUE) were trading down more than 20 percent on Thursday morning. The decline seems to have been triggered both by the company's earnings call and updated trial data for the treatment of beta-thalassemia. Noted biotech analyst Jason Napodano weighed...

The "specialty pharma" space has received a lot of attention this week, and it's not very positive. It began on Monday with a New York Times article focusing on "Prescriptions Made easy." The market felt the effects on Wednesday when Citron Research came out with a...

Benzinga recently had the chance to chat with Jason Napodano, biopharma analyst and consultant, owner of BioNap Consulting and former biotech analyst at Zacks. Below are just a few of the expert’s comments on potential M&A activity and partnerships in the biotech segment in the current...

Benzinga recently had the chance to talk with Jason Napodano, biopharma analyst and consultant, and owner of BioNap Consulting. Below is a look at some highlights from the expert. Macro Conditions And The Biotech Industry When asked about the current state of macro conditions for the biotech...